KOSDAQFood & Beverage082850

Wooree Bio

₩3,390▼ 1.74%2026-11-18 close
Market Cap
₩32.9B
Turnover
₩29,711,245
Volume
8.7K
Shares out.
9.7M
PER
—
PBR
0.2×
EPS
-₩1,501
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

Revenue up three quarters running, profit still in the red

Wooree BIO's Q3 2026 revenue rose 32.7% year on year to KRW 350.2 billion, yet an operating loss of KRW 5.12 billion keeps profitability the central question.

  1. 1

    Revenue: after the Q4 2025 low, sales rose in each of the three quarters through Q3 2026, reaching KRW 350.2 billion in Q3.

  2. 2

    Profit: operating losses ran through Q1 to Q3 2026, and the last four quarters' net loss attributable to controlling shareholders totals KRW 14.2 billion.

  3. 3

    Balance sheet: the debt ratio climbed from 126.5% in 2024 to 191.5% in 2025, with total liabilities of KRW 500.6 billion against total equity of KRW 261.3 billion.

  4. 4

    Portfolio: health functional foods (mainly domestic sales), LED modules and electronic components (mainly exports) and medical cannabis research operate side by side.

  5. 5

    Valuation: with net losses over the last four quarters, an earnings-based PER cannot be calculated, and the price-to-book ratio sits below its level at the end of 2023.

02

Business structure

Wooree BIO was founded in 2000 and listed on KOSDAQ. As of September 2025 it operated four domestic corporations and nine overseas corporations, including ones in China and Vietnam.

Its core businesses are natural-ingredient health functional foods, LED package modules and electronic components, and bio operations that include medical cannabis cultivation research.

On the LED side, subsidiaries Wooree E&L (LED package manufacturing), New Optics (LED backlight units), Shinbo Electronics (BLU and parts) and Hyangrim Electronics (LED BLU and set-TV parts) are active, and the New Optics group also runs TV sales and assembly entities.

In the 2024 domestic and export mix, health functional foods were 99.99% domestic, while LED PKG modules and similar products were 97.2% exports. Food segment revenue was about KRW 73 billion in 2024, roughly 6% of the total. R&D expense was KRW 15.36 billion in 2024, equal to 1.24% of revenue.

The company received approval for medical cannabis cultivation and research in 2021 and is upgrading cultivation technology through its subsidiary Wooree Green Science. Its company profile also says it aims to develop a health subscription service built on DNA analysis technology.

The largest shareholder group, led by Woorienterprise and four related parties, held 34.29%, and treasury shares were 2.58% (as of September 2025).

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩263.9B₩2.4B0.9%
2025Q4₩250.8B₩200M0.1%
2026Q1₩269.2B-₩4.3B−1.6%
2026Q2₩316.4B-₩2.4B−0.8%
2026Q3₩350.2B-₩5.1B−1.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.4T₩34.4B₩21.8B2.5%12.2%146.5%
2023₩1.3T₩26B₩15.6B2.1%7.8%133.2%
2024₩1.2T₩15.2B₩4.7B1.2%2.2%126.5%
2025₩1T₩1B-₩9.4B0.1%−4.6%191.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show that revenue and operating profit each fell for three consecutive years from 2023 to 2025. Revenue went from KRW 1.36 trillion in 2022 to KRW 1.26 trillion in 2023 (down 6.7% year on year), KRW 1.24 trillion in 2024 (down 2.1%) and KRW 1.04 trillion in 2025 (down 15.6%).

Operating profit declined from KRW 34.4 billion in 2022 to KRW 26 billion in 2023 and KRW 15.2 billion in 2024, then to KRW 952 million in 2025. The operating margin moved from 2.5% in 2022 to 2.1% in 2023, 1.2% in 2024 and 0.1% in 2025.

Net profit attributable to controlling shareholders was KRW 4.74 billion in 2024, but 2025 turned into a net loss of KRW 9.37 billion, and the net loss including non-controlling interests was KRW 10.2 billion.

The company attributed the 2025 decline to lower sales across its business units amid a global economic slowdown, along with higher cost of sales such as raw materials. The balance sheet also shifted in 2025, with the debt ratio rising from 126.5% in 2024 to 191.5%.

Quarterly results turned from KRW 2.37 billion of operating profit in Q3 2025 to KRW 154 million in Q4 2025, when revenue was KRW 250.8 billion (down 5.0% from the prior quarter).

Revenue then rose to KRW 269.2 billion in Q1 2026 (up 7.4%), KRW 316.4 billion in Q2 (up 17.5%) and KRW 350.2 billion in Q3 (up 10.7%), a three-quarter run of gains. Over the same period operating losses were KRW 4.31 billion in Q1 2026, KRW 2.42 billion in Q2 and KRW 5.12 billion in Q3, three straight loss quarters.

In Q1 2026 the company still posted net profit attributable to controlling shareholders of KRW 2.18 billion despite the operating loss, and the controlling-shareholder net loss widened to KRW 15.2 billion in Q3.

Because the net loss attributable to controlling shareholders was much larger than the operating loss in some quarters, non-operating items and tax effects weighed heavily on earnings.

Cumulative operating loss for January to September 2026 was KRW 11.86 billion, against operating profit of KRW 799 million in the same period of 2025, according to the quarterly report. Revenue has grown, but profit has not followed.

05

Industry analysis

Wooree BIO's businesses sit in different industry cycles. The LED segment faces a long-running oversupply, according to a September 2025 corporate analysis, as LED TV penetration rises and Chinese makers invest aggressively, with Chinese LEDs improving in performance while their prices fall and squeezing profitability.

Because 97.2% of LED PKG module sales in 2024 were exports, the company is directly exposed to Chinese price competition and changes in overseas demand. Health functional foods were 99.99% domestic sales in 2024, so that business depends on domestic consumption and the regulatory environment.

Medical cannabis has been in research and development since its 2021 approval, and the timing of revenue contribution is a medium- to long-term variable.

The company is classified under food and beverages, but electronic components, health functional foods and bio operations coexist, so sector averages alone cannot explain its earnings drivers. Unlike food-focused large peers, the price cycle of its LED business feeds directly into group results.

Its share price has moved strongly on cannabis-theme trading, so business value and share price movements are worth distinguishing.

06

Outlook

The next periodic report is the 2026 annual report, and Q4 2026 results have not yet been disclosed. Because operating losses ran through January to September 2026, whether the full-year operating margin improves on the 0.1% of 2025 is the first item to check.

Net loss attributable to controlling shareholders totals KRW 14.2 billion over the last four quarters, so the direction of non-operating items and financing costs remains a variable for full-year net income.

The debt ratio rose to 191.5% at the end of 2025, so whether total liabilities shrink relative to total equity in the annual report is the financial checkpoint.

In the food segment, the key question is whether customer relationships and sales recover after the reported 120-day business suspension over additive violations. Food accounts for roughly 6% of revenue, so its scale is limited, but the effect of a long suspension on customer relationships is a separate issue.

Medical cannabis remains a research-stage business, making commercialization timing a medium- to long-term variable. Whether revenue growth continues through the next quarters, and whether it translates into narrower losses, will be the benchmark for reading upcoming results.

07

Valuation

PER
—
PBR
0.2×
ROE
-7.2%
EPS
-₩1,501
BPS
₩20,118
Dividend per share
—

Wooree BIO's valuation reads better on asset-based measures than earnings-based ones given current data. With net losses over the last four quarters, an earnings-based PER cannot be calculated.

On the disclosed figures, PER could be computed for 2023 and 2024, but turned uncalculable in 2025 because of net losses, so whether a multiple can be shown depends on a return to earnings.

The price-to-book ratio was lower at the end of 2025 than at the end of 2023, and the stock still trades at a low level relative to net assets.

Shareholders' equity attributable to controlling shareholders was KRW 204.8 billion at the end of 2025, so book value is large, but because profit attributable to controlling shareholders is negative, that book value is not yet translating into earnings.

The debt ratio rising to 191.5% also means liabilities are heavier relative to equity than before, which affects how book value should be read. The 2025 settlement included a small cash dividend, but whether dividends can continue while the company is loss-making depends on a recovery in earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly revenue recovery

From the Q4 2025 low of KRW 250.8 billion, revenue rose to KRW 269.2 billion in Q1 2026, KRW 316.4 billion in Q2 and KRW 350.2 billion in Q3, three straight quarterly gains. Q3 revenue grew 32.7% year on year, and cumulative January to September 2026 revenue of KRW 935.8 billion was 18.0% higher than a year earlier. The recovery in sales scale can be read as a sign of business normalization.

Capital base and book value gap

Total equity at the end of 2025 was KRW 261.3 billion, of which KRW 204.8 billion belonged to controlling shareholders. The share price trades well below book value attributable to controlling shareholders, which bulls cite as an asset-based argument. The lower price-to-book ratio compared with the end of 2023 is also raised in the same context.

Diversified business portfolio

Health functional foods were 99.99% domestic sales in 2024, anchoring the business in domestic consumption, while LED exports were 97.2% of their segment, tying it to overseas demand.

Medical cannabis holds a 2021 cultivation and research approval, and the company is upgrading cultivation technology through its subsidiary Wooree Green Science. With three segments serving different customers, the impact of weakness in one business can be spread across the group.

09

Bear factors

Three straight quarters of operating losses

Operating losses were KRW 4.31 billion in Q1 2026, KRW 2.42 billion in Q2 and KRW 5.12 billion in Q3, three consecutive loss quarters. The Q3 loss widened, turning from operating profit of KRW 2.37 billion in the same quarter of 2025 into a loss.

Cumulative operating loss for January to September 2026 reached KRW 11.86 billion, so revenue growth has not translated into better profit.

Rising debt burden

The debt ratio jumped to 191.5% in 2025 from 126.5% in 2024. Total liabilities at the end of 2025 were KRW 500.6 billion, exceeding total equity of KRW 261.3 billion.

Operating cash flow stayed positive, but with a net loss attributable to controlling shareholders of KRW 14.2 billion over the last four quarters, borrowing costs remain a key area to monitor.

Impact of prolonged oversupply

One corporate analysis says LED profitability is deteriorating as Chinese LEDs improve in performance while prices fall. With 97.2% of LED PKG module sales exported in 2024, the segment bears price competition directly.

If profitability in electronic components does not recover, the scope for group operating margin improvement could remain limited.

10

Risk factors

Regulation and quality

The food business faced a 120-day business suspension after seven products were found in violation of food additive standards, according to press reports. The reports also noted that additive violations cannot be replaced with a fine under food hygiene rules.

Food revenue was about KRW 73 billion in 2024, roughly 6% of the total, so the revenue weight is small, but the risk of customer losses and reputational damage could be significant.

Financial structure

The debt ratio rose to 191.5% at the end of 2025, increasing the debt burden. Net loss attributable to controlling shareholders over the last four quarters totals KRW 14.2 billion, and the Q3 2026 loss widened to KRW 15.2 billion. If additional funding is needed, interest costs could delay a return to profitability.

Theme trading and liquidity

Press reports have linked share price swings to theme-driven trading tied to medical cannabis expectations. In August 2026 the company disclosed a trading halt in its common shares for a share consolidation, starting August 14, 2026.

With the largest shareholder group holding 34.29% (as of September 2025), the share price may be sensitive to changes in trading supply.

11

What to watch next

  1. Mid-February 2027

    Preliminary full-year 2026 results. Based on the prior year's disclosure on February 12, 2026, a similar timing is likely. Check whether the operating margin improves on 0.1% in 2025 and whether operating losses continue.

  2. End of March 2027

    Deadline for the 2026 annual report (90 days after fiscal year-end). Review the full-year operating margin, debt ratio and operating cash flow, and check the segment commentary for food sales recovery after the suspension.

  3. Mid-May 2027

    Deadline for the Q1 2027 quarterly report. Check whether quarterly operating losses continue and how the debt ratio moves from 191.5% at the end of 2025.

12

Overall view

Wooree BIO's Q3 2026 results combine revenue growth with a wider operating loss. From the Q4 2025 low, revenue rose for three straight quarters to KRW 350.2 billion, while operating losses continued for three consecutive quarters over the same period.

On disclosed annual figures, revenue and operating profit each fell for three years from 2023 to 2025, and the operating margin declined from 2.5% in 2022 to 0.1% in 2025. The company swung to a net loss attributable to controlling shareholders of KRW 9.37 billion in 2025, and the debt ratio rose to 191.5%.

On the bull side, the cited points are the revenue recovery, equity of KRW 261.3 billion at the end of 2025, a lower price-to-book ratio and a portfolio spanning health foods, LED and cannabis.

On the bear side, the main points are three straight quarters of operating losses, a net loss attributable to controlling shareholders of KRW 14.2 billion over the last four quarters, the reported food-segment suspension and price competition from Chinese LED makers.

The next items to track are the full-year 2026 preliminary results, the operating margin in the 2026 annual report and the direction of the debt ratio.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. vegannews.co.kr
  4. comp.wisereport.co.kr
  5. m.news.nate.com
  6. seo.goover.ai
  7. k5.co.kr
  8. m.dailypharm.com
  9. kpinews.kr
  10. pharm.edaily.co.kr
  11. vegannews.co.kr
  12. thinkpool.com
  13. ebn.co.kr
  14. biztribune.co.kr
  15. medipana.com
  16. comp.fnguide.com
  17. thebionews.net
  18. supple.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis